|
# # # # LRRK2 inhibition represents one of several biological approaches to slowing the progression of Parkinson’s that is currently being clinically tested. Leading the charge in the development of LRRK2 inhibitors is a biotech company called Denali Therapeutics (in partnership with Biogen). Recently, the company provided news on the immediate future clinical development plans for their lead molecule BIIB122. In today’s post, we will look at what is going to happen next for LRRK2 inhibition. # # # # |
Source: Denali
Founded in 2013 by a group of former Genentech executives, San Francisco-based Denali Therapeutics is a biotech company which is focused on developing novel therapies for people suffering from neurodegenerative diseases.
In particular, they have been leading the charge on a new class of drugs for Parkinson’s called LRRK2 inhibitors.
What are LRRK2 inhibitors?
The Science of Parkinson's 